ifchairscouldtalk writes "A Phase III 'RV 144' study in Thailand succeeded in reducing HIV infection rate in trial with 31.2% effectiveness. The study was conducted by the Thailand Ministry of Public Health and used strains of HIV common in Thailand. It is not clear whether the vaccine, which combines AIDSVAX with Aventis Pasteur ALVAC-HIV canarypox vector, known as 'vCP1521,' would work against other strains in the United States, Africa or elsewhere. Strangely, the vaccine had no effect on levels of HIV in the blood of those who did become infected, providing 'one of the most important and intriguing findings' of the trial, according to Dr Fauci, director of the National Institute of Allergy and Infectious Diseases, which is one of the trial's sponsors."
DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Also, Slashdot's Facebook page has a chat bot now. Message it for stories and more. Check out the new SourceForge HTML5 Internet speed test! ×